B.Riley analyst Mayank Mamtani reiterated a Buy rating and $74.00 price target on Harrow Health (NASDAQ: HROW)The analyst comments "VEVYE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE